[go: up one dir, main page]

MX2017015496A - Fosforilacion selectiva sin disolvente. - Google Patents

Fosforilacion selectiva sin disolvente.

Info

Publication number
MX2017015496A
MX2017015496A MX2017015496A MX2017015496A MX2017015496A MX 2017015496 A MX2017015496 A MX 2017015496A MX 2017015496 A MX2017015496 A MX 2017015496A MX 2017015496 A MX2017015496 A MX 2017015496A MX 2017015496 A MX2017015496 A MX 2017015496A
Authority
MX
Mexico
Prior art keywords
formula
solvent free
selective solvent
salts
preparation
Prior art date
Application number
MX2017015496A
Other languages
English (en)
Inventor
Redpath Philip
CROSSEY Kerri
Eugenie MIGAUD Marie
RHONEMUS Troy
Cunningham Richard
Venkataraman Sylesh
Original Assignee
Chromadex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chromadex Inc filed Critical Chromadex Inc
Publication of MX2017015496A publication Critical patent/MX2017015496A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/048Pyridine radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576Six-membered rings
    • C07F9/58Pyridine rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00Processes for the preparation of sugar derivatives
    • C07H1/02Phosphorylation
    • C07H1/04Introducing polyphosphoric acid radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16Purine radicals
    • C07H19/20Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

Se proporciona un proceso sintético para la preparación de análogos fosforilados de ribósido de nicotinamida ("NR") que tienen la fórmula (I), o sales de los mismos, y derivados reducidos o modificados de los mismos, que tienen la fórmula (II), en la que X-, Yl, Y2, Z', Z2, n, RI, R2, R3, R4, R5, R6 y R7 son como se definen en el presente documento. La presente divulgación también se refiere a la preparación de análogos fosforilados de ribósido de ácido nicotínico ("NAR") que tienen la fórmula (I), o sales de los mismos, y derivados reducidos o modificados de los mismos, que tienen la fórmula (II). Generalmente, se emplean condiciones sin disolvente usando técnicas mecano-químicas apropiadas como se describen. (I) (II).
MX2017015496A 2015-06-04 2016-06-03 Fosforilacion selectiva sin disolvente. MX2017015496A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562171138P 2015-06-04 2015-06-04
PCT/US2016/035729 WO2016196941A1 (en) 2015-06-04 2016-06-03 Selective solvent free phosphorylation

Publications (1)

Publication Number Publication Date
MX2017015496A true MX2017015496A (es) 2018-08-01

Family

ID=57441978

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017015496A MX2017015496A (es) 2015-06-04 2016-06-03 Fosforilacion selectiva sin disolvente.

Country Status (10)

Country Link
US (1) US20160355539A1 (es)
EP (1) EP3302059A4 (es)
JP (1) JP2018517709A (es)
KR (1) KR20180033465A (es)
CN (1) CN107846883A (es)
AU (1) AU2016271481A1 (es)
BR (1) BR112017025969A2 (es)
CA (1) CA2987986A1 (es)
MX (1) MX2017015496A (es)
WO (1) WO2016196941A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108137639B (zh) 2015-08-05 2021-10-08 麦德龙国际生物科技有限责任公司 烟酰胺单核苷酸衍生物及其用途
GB2542881B (en) 2015-10-02 2020-01-01 Carr Andrew Crystal forms of ß-nicotinamide mononucleotide
EP3538099A4 (en) 2016-11-11 2020-06-17 The Queen's University of Belfast EFFICIENT AND SCALABLE SYNTHESIS OF NICOTINOYL RIBOSIDES AND REDUCED NICOTINOYL RIBOSIDES, MODIFIED DERIVATIVES THEREOF, PHOSPHORYLATED ANALOGS OF THEM, ADENYLYDINUCLEOTIDE CONJUGATES THEREOF AND NEW-WAY CRYSTALS
US11071747B2 (en) 2016-11-29 2021-07-27 University Of Iowa Research Foundation Use of NAD precursors for breast enhancement
BR112019010607B1 (pt) 2016-11-29 2023-10-31 University Of Iowa Research Foundation Uso de precursores de nad e composição compreendendo os referidos precursores
CA3059228C (en) * 2017-04-05 2025-03-18 Cornell University BETA-NICOTINE ESTER NUCLEOTIDES AND PREPARATION METHODS
CN108976259A (zh) * 2017-06-01 2018-12-11 上海凯赛生物技术研发中心有限公司 一种磷酸吡哆醛的合成方法
EP3642214A2 (en) 2017-06-19 2020-04-29 Gangadhara Ganapati Nicotinamide riboside derivatives and their uses
WO2019152416A1 (en) 2018-01-30 2019-08-08 Metro International Biotech, Llc Nicotinamide riboside analogs, pharmaceutical compositions, and uses thereof
KR20210118356A (ko) * 2018-05-15 2021-09-30 점프스타트 퍼틸리티 피티와이 엘티디 노화방지제로서의 니코틴산 모노뉴클레오타이드의 무기 염
JP7432585B2 (ja) * 2018-05-15 2024-02-16 ジャンプスタート ファーティリティ ピーティーワイ リミテッド 抗加齢剤としてのニコチン酸モノヌクレオチド及びニコチンアミドモノヌクレオチドのアミノ酸塩
WO2020072497A1 (en) * 2018-10-01 2020-04-09 Cornell University Methyl and ethyl nicotinate-riboside-5-phosphates, preparation thereof and methods of use thereof
US11833167B2 (en) 2018-12-17 2023-12-05 Mitopower Llc Nicotinyl riboside compounds and their uses
US10618927B1 (en) 2019-03-22 2020-04-14 Metro International Biotech, Llc Compositions and methods for modulation of nicotinamide adenine dinucleotide
US11939348B2 (en) 2019-03-22 2024-03-26 Metro International Biotech, Llc Compositions comprising a phosphorus derivative of nicotinamide riboside and methods for modulation of nicotinamide adenine dinucleotide
CN110483601A (zh) * 2019-08-12 2019-11-22 上海龙翔生物医药开发有限公司 制备β-烟酸胺单核苷酸的方法及其应用
KR20240020716A (ko) 2021-05-27 2024-02-15 메트로 인터내셔널 바이오테크 엘엘씨 니코틴산 모노뉴클레오타이드 및 이의 에스터의 결정질 고체 및 제조 및 사용 방법
CN118613472A (zh) * 2022-01-31 2024-09-06 新前沿生物公司 基于烟酸酯和烟酰胺核苷的化合物及其衍生物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1042839A (en) * 1963-12-19 1966-09-14 Asahi Chemical Ind Production of 5'-nucleotides
AU2003208999A1 (en) * 2002-02-06 2003-09-02 Iowa State University Research Foundation, Inc. Solvent-free mechanochemical preparation of phosphonium salts, phosphorus ylides, and olefins
JP5663576B2 (ja) * 2010-07-06 2015-02-04 秀則 上西 神経突起伸長剤

Also Published As

Publication number Publication date
WO2016196941A1 (en) 2016-12-08
CA2987986A1 (en) 2016-12-08
CN107846883A (zh) 2018-03-27
US20160355539A1 (en) 2016-12-08
EP3302059A4 (en) 2018-10-03
KR20180033465A (ko) 2018-04-03
BR112017025969A2 (pt) 2018-08-07
JP2018517709A (ja) 2018-07-05
AU2016271481A1 (en) 2017-12-14
EP3302059A1 (en) 2018-04-11

Similar Documents

Publication Publication Date Title
MX2017015496A (es) Fosforilacion selectiva sin disolvente.
SG11201810655QA (en) Method for producing substituted polycyclic pyridone derivative and crystal of same
NZ803738A (en) Efficient and scalable syntheses of nicotinoyl ribosides and reduced nicotinoyl ribosides, modified derivatives thereof, phosphorylated analogs thereof, adenylyl dinucleotide conjugates thereof, and novel crystalline forms thereof
EP4365179A3 (en) Novel rapamycin derivatives
PH12014501719A1 (en) Pyridone derivatives
SG11201900869QA (en) Pharmaceutical compositions containing substituted polycyclic pyridone derivatives and prodrug thereof
TR201802791T4 (tr) Aril ve heteroaril füzyonlu laktamlar.
MX2013007490A (es) Derivados de aminodihidrotiazina fusionada.
CA2875877C (en) Syk inhibitors
BR112017023540A2 (pt) síntese de derivados de 1 h-pirrolo[2,3-b]piridin que modulam quinases
MX349969B (es) Metodos de preparación de ribósido de nicotinamida y sus derivados.
JO3453B1 (ar) مشتقات البنزاميد لتثبيط نشاط abl1 و abl2 و bcr-abl1
MX368882B (es) Proceso para la preparacion de triazinas.
PH12015501585A1 (en) Manufacturing process for pyrimidine derivatives
PH12015501363B1 (en) Chloro-pyrazine carboxamide derivatives with epithelial sodium channel blocking activity
MY194307A (en) Pyridone derivative having tetrahydropyranylmethyl group
PH12015501226A1 (en) Crystalline 6,7-unsaturated-7-carbamoyl morphinane derivative, and method for producing the same
AU2018253590A1 (en) Imidazopyridazine compounds
NZ718487A (en) Fused heterocyclic compound, preparation method therefor, pharmaceutical composition, and uses thereof
MX394421B (es) Derivados de piridona policiclica sustituida y profarmaco de los mismos
MX2018001145A (es) Métodos para la preparación de ácidos biliares y derivados de los mismos.
PH12014501711A1 (en) Benzyl sulfonamide derivatives useful as mogat-2 inhibitors
MA39715A (fr) Formes polymorphes de l'acide 4,5-dihydro-1h-pyrrolo[2,3-f]quinoline-2,7,9-tricarboxylique et de son sel de disodium, procédé de préparation desdites formes polymorphes et leur utilisation
NZ711343A (en) Sodium salt of (2s, 5r)-6-benzyloxy-7-oxo-1,6-diaza-bicyclo [3.2.1 ] octane-2-carboxylic acid and its preparation
ZA201805790B (en) Improved process for the preparation of osimertinib (azd9291) or a salt thereof, and "azd9291 aniline" or a salt thereof